
Analysing the Strategic Acquisition of Biocon Biologics’ India-Branded Formulations by ERIS Lifesciences
In a landmark deal within the Indian pharmaceutical sector, ERIS Lifesciences has acquired the India-branded formulations business of Biocon Biologics for Rs. 1242 Crore ($150 million), equivalent to 3.4 times the revenue. This acquisition marks ERIS Lifesciences’…
Read more
Most Commented